Biocon Confident As First Biosimilars Seen Hitting Europe In Early 2018
Executive Summary
India’s leading biologics company Biocon has said it expects its first biosimilar products to be launched in the European market by early 2018 and is bullish on both its plans in the sector and earnings prospects after reporting quarterly net profit soared by a better than expected 52%.
You may also be interested in...
Samsung Enters Oncology as Trastuzumab Accepted For EU Review
Samsung Bioepis's trastuzumab has become the South Korean company’s fifth biosimilar candidate to be filed for approval in Europe and also marks its planned entry into the oncology sector in the region.
Top US Court Lifts Discovery Stay On Price-Fixing
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.
FDA Approves First Generic Of Daraprim
Daraprim, which saw its price jacked up by 4,000% by former drug company executive Martin Shkreli, now has a competitor with the US Food and Drug Administration’s approval of the first generic version of the nearly seven-decade-old drug used to treat a life-threatening parasitic infection known as toxoplasmosis.